v3.26.1
Cover
Apr. 22, 2026
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag true
Amendment Description This Amendment No. 1 on Form 8-K/A (this “Amendment”) amends the Current Report on Form 8-K filed by Indaptus Therapeutics Inc. with the U.S. Securities and Exchange Commission on April 23, 2026 (the “Original Report”). This Amendment is being filed solely to reflect that, subsequent to the filing of the Original Report, the Company was informed by the director identified in the Original Report as Yí Zhang (Johnny) that he had changed his legal name to Johnny Fox Arrowsmith. Dr. Arrowsmith uses “Yi Zhang” as his professional name. The disclosure in the Original Report has been updated accordingly to reflect the director’s current legal name. Except as expressly set forth herein, this Amendment does not modify or update any other disclosures contained in the Original Report, and this Amendment should be read in conjunction with the Original Report. The Original Report otherwise continues to speak as of the date originally filed.
Document Period End Date Apr. 22, 2026
Entity File Number 001-40652
Entity Registrant Name INDAPTUS THERAPEUTICS, INC.
Entity Central Index Key 0001857044
Entity Tax Identification Number 86-3158720
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 3 Columbus Circle 15th Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10019
City Area Code (646)
Local Phone Number 427-2727
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value
Trading Symbol INDP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false